To clarify post #529 based on a few comments I've received:
Any opinions that I expressed in that post are strictly my own, and do not reflect those of Bayer Corp. I have no knowledge of Bayer's opinion of Matritech's technology, and if I did have any knowledge, it would be both unethical and illegal for me to divulge that knowledge. Any information that I gave in that post is my personal interpretation of the Dec 4 and Oct 16 press releases from Matritech, and the Dec 15 press release from IMII.
I have worked in the medical diagnostics business for a number of years, and it is my opinion based on published data that Matritech has developed, or is in the process of developing diagnostic tests with superior clinical utility. I have also observed that in the past Matritech has consistently met its development milestones in their marketing agreement with Bayer as we all know through their press releases.
Although I don't know what the ultimate outcome will be with the Matritech/Bayer agreement, my guess is that Matritech will ultimately strike a deal with some diagnostics manufacturer to automate the cervical screening test. Cervical screening is a lab test that is begging for automation. It is a high volume, labor intensive test, and Matritech's antibody could be adapted in a number of different ways to automate the test. I think in the long term the cervical test has the potential to bring a lot of revenue to Matritech irregardless of who their business partnership is with.
For the short term, I also expect at least a temporary increase in the stock based on the 510(k) filing for the colon test that was made in mid October. If they made a good filing (accurate and complete), they should be hearing from the FDA some time in January. If you remember, the stock went from 3 to 18 when they received FDA approval for their bladder test. The 510(k) process typically takes 3 months for diagnostic tests, but can be delayed if the reviewer feels he or she needs more information. In this case, the holidays may also add a delay.
My bet is that now is the perfect time to look for buying opportunities in anticipation of the 510(k) clearance. |
